Fig. 5From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trialsMean change from baseline in headache-related disability, as measured by (a) MIDASa and (b) HIT-6b. CM, chronic migraine; EM, episodic migraine; HIT-6, 6-item Headache Impact Test; MAMD, monthly average migraine days; MIDAS, Migraine Disability Assessment; SE, standard error. aFor participants with EM, response was defined as a reduction of ≥ 2 MAMD. bFor participants with CM, response was defined as a reduction of ≥ 4 MAMDBack to article page